Additionally, it was shown that in hemophilia B patients with circulating anti-AAV5 antibodies, factor IX transduction was effective and comparable, regardless of the level of pre-existing anti-AAV5 NAB levels (Majowicz et al. 2019). This evidence concerns the gene F9 and hemophilia B.